Gynecological Cancers Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Gynecological Cancers Therapeutics Market 2024-2028

The global gynecological cancers therapeutics market size is estimated to grow by USD 19.15 billion at a CAGR of 15.83% between 2023 and 2028. 

The pipeline for treating gynecological cancers is advancing with novel therapeutics, including vaccines, gene therapy, and targeted therapy products. While gene therapy is in early clinical development, targeted therapy and vaccine products are in late stages, with some anticipated to launch in the forecast period. These innovations, employing mechanisms like PD-L1 inhibition, cell cycle inhibition, angiogenesis inhibition, and PARP inhibition, are poised to transform gynecological cancer treatment. Clinical trials predominantly focus on combination therapies, but several companies are dedicated to developing unique targeted therapies. Notably, Atezolizumab and vaccines like Z-100 and an Advaxis therapeutic vaccine, currently in Phase III trials, show promise for cervical cancer treatment. The market is witnessing accelerated approvals, with three PARP inhibitors such as Lynparza, Rubraca, and ZEJULA. Regulatory approvals for drugs like Lynparza and Zejula, particularly for ovarian cancer, indicate a positive trajectory, driving growth in the market during the forecast period.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Type, Modality and Geography Analysis

Type Analysis 

Uterine cancer

The market share growth by the uterine cancer segment will be significant during the forecast period. Uterine cancer begins in the layer of cells that form the inner lining of the uterus. There are different types of uterine cancer, and the most common one is endometrial cancer, which originates in the endometrium or the inner lining of the uterus. The treatment of uterine cancer involves the surgical removal of the uterus (hysterectomy) followed by radiation and chemotherapy.

Get a glance at the market contribution of various segments Download PDF Sample

The uterine cancer was the largest and was valued at USD 4.24 billion in 2018. Depending on the stage of cancer, a combination of standard chemotherapy drugs, including paclitaxel, carboplatin, doxorubicin, ifosfamide, and cisplatin, is used. Research in this therapy area mainly revolves around the use of novel chemotherapy regimens to improve the survival rate in patients. Research on identifying novel targets for therapeutics is also underway. Evaluation is underway to understand the potential of drugs that affect apoptosis, anti-angiogenic agents, signal transduction, epidermal growth factor receptor inhibitors, and epigenetic modification in endometrial cancer. Similar pipeline advances being made by pharmaceutical companies are expected to change the treatment landscape and, thereby, the market size of the uterine cancer type segment, which in turn is expected to drive the growth of the market during the forecast period.

Modality Analysis 

Chemotherapy

Chemotherapy remains a dominant therapeutic modality sub-segment in the market, playing a critical role in the treatment of ovarian, cervical, and endometrial malignancies. It entails the use of cytotoxic medicines to prevent the proliferation of cancer cells by disrupting their deoxyribonucleic acid (DNA) or cell division processes. Cisplatin and paclitaxel, both platinum-based medicines, are routinely used in gynecological cancer chemotherapy regimens. Furthermore, combination therapies like carboplatin and paclitaxel have shown efficacy in treating later stages. Chemotherapy's widespread use is owing to its demonstrated efficacy in lowering tumor burden and improving survival rates. Chemotherapy is likely to maintain its dominance the market as research continues to optimize chemotherapy protocols, research novel drug combinations and targeted therapies, and provide vital alternatives for patients undergoing treatment. Chemotherapy's side effects include harm to healthy cells, resistance development, a weaker immune system, and a negative impact on quality of life. Owing to such factors, the market is expected to witness growth during the forecast period.

Targeted therapy

Targeted therapy is emerging as a significant therapeutic technique in the  market, providing precision in treatment while minimizing side effects. PARP inhibitors such as Olaparib for ovarian cancer and Trastuzumab for HER2-positive endometrial cancer are two prominent examples of targeted therapies. These treatments target specific molecular or cellular targets associated with cancer, halting its progression. Targeted therapy has demonstrated significant success in improving outcomes for gynecological cancer patients, leading to increased acceptance in clinical practice. The targeted therapy segment is poised for significant growth as research continues to find novel targets and molecular pathways, contributing to a more personalized and successful approach in the treatment of gynecological tumors globally. Drug resistance, limited efficacy in specific subtypes, potential adverse effects, high costs, and the need for personalized treatment regimens are among the challenges confronting targeted therapy in gynecological cancer. Such factors are expected to drive the growth of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. Market growth in North America can be attributed to four major factors, which include the growing incidence of gynecological cancers, the availability of favorable reimbursement schemes, government initiatives, and approvals of new drugs for gynecological cancers like ovarian and cervical cancers. The rise in the incidence of gynecological cancers in countries such as the US and Canada is driving market growth in North America. For instance, it is estimated that around 14,100 women living in the US will be diagnosed with cervical cancer, and more than 4,280 women may die from cervical cancer in 2022 despite undergoing screening and treatment. Similarly, it has been estimated by the Centers for Disease Control and Prevention (CDC) that ovarian cancer brings more deaths than any other type of gynecological cancer. 

In addition, the rising incidence of gynecological cancers, favorable reimbursement schemes are driving market growth in North America. Medicare, a federal government program for healthcare in the US, covers chemotherapy for cancer patients under Part B (medical insurance program). Moreover, the Medicare program covers one Pap test and pelvic exams every two years if a woman has an average risk for cervical cancer. Additionally, if a woman has an abnormal Pap test in the previous three years, Medicare covers the cost of diagnostic tests done in subsequent years. Such factors are expected to drive the regional market growth during the forecast period. 

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc.  -The company offers gynecological cancers therapeutics such as Elahere (mirvetuximab soravtansine-gynx) which is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).

• Amgen Inc.
• Apotex Inc.
• AstraZeneca Plc
• Bayer AG
• Bristol Myers Squibb Co.
• Cipla Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, market trends and analysis, and challenges. 

Key Drivers

The rising number of patient assistance programs is notably driving market growth. The need to address the economic and emotional burden associated with gynecological cancers is encouraging manufacturers, governments, non-profit organizations, and healthcare providers to improve patient access to resources and bridge the substantial gaps in healthcare. Since the cost of chemotherapy can have a huge financial impact on patients without insurance, many leading manufacturers of these therapies are providing financial assistance to patients with gynecological cancers. For instance, GlaxoSmithKline plc launched the 'GSKforyou' program, which provides assistance to the uninsured, Medicare prescription coverage, vaccine assistance, and other resources to reduce the economic burden arising as a result of treatment for different health conditions, including gynecological cancers. 

For instance, co-payment programs such as the Patient Advocate Foundation's Co-Pay Relief Program provide financial support to low-income patients who have insurance but need to pay out of their pockets as part of the total treatment cost. The Colorado Ovarian Cancer Alliance (COCA) focuses on promoting awareness of the early detection of ovarian cancer. COCA also provides assistance as a part of the COCA. Cares program, under which COCA pays the bills of patients undergoing treatment. Such factors are expected to drive the growth of the market during the forecast period.

Significant  Trends

Rising awareness of gynecological cancers is an emerging trend shaping market growth. Multiple organizations are striving to increase awareness among people about gynecological cancers. For instance, the CDC conducts a campaign called Inside Knowledge: Get the Facts About Gynecologic Cancer, which provides the public with access to information about gynecological cancers. Worldwide events such as Ovarian Cancer Awareness Month and Uterine Cancer Awareness Month conducted in September also aim to raise awareness about these diseases. Likewise, the US Foundation for Women's Cancer observes September as the Gynecologic Cancer Awareness Month every year. Some organizations work toward increasing patient awareness regarding all the major sub-types of gynaecological cancer.

For instance, Target Ovarian Cancer works toward increasing the awareness of ovarian cancer with its campaigns that focus on early diagnoses and clinical trials. Another example is the National Cervical Cancer Coalition, which has multiple local chapters across the US and highlights issues regarding cervical cancer. The American Cancer Society also works to promote awareness of cancers like cervical cancer and encourages women to get tested for cervical cancer. Such factors are expected to drive the market growth and trends during the forecast period.

Major  Challenges

Challenges in reimbursement are a significant challenge hindering market growth. In the case of gynecological cancers such as ovarian cancer, although the reimbursement scenario is favorable, there are several restrictions to adequate reimbursement. For instance, under the Medicare program in the US, reimbursement schemes are limited to outpatient drugs. Under the program, there are no reimbursement schemes available for oral drugs. Oral drugs are reimbursed only when the drug is available as an intravenous formulation. Hence, even though cost-effective oral chemotherapy agents are available for the treatment of ovarian cancer, many are not offered to patients as they are not covered by Medicare.

Furthermore, in the case of endometrial cancer, health insurers generally do not provide coverage for most new therapies. Codes for reimbursement for endometrial cancer treatment are available with an assigned reimbursement tariff. But, the main problem arises when the length of stay extends beyond the number of days specified in the code specified for reimbursement. Such factors will hinder the growth of the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market forecasting report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market analysis and report also include key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Market Analyst Overview

The market is witnessing significant growth, driven by increasing awareness and advancements in treating cancers affecting reproductive organs in females. The market encompasses drugs targeting various gynecological cancers, including those affecting the peritoneum, ovary, fallopian tubes, vagina, vulva, cervix, and the muscles and tissues supporting the uterus. These therapeutics address abnormal cell growth leading to conditions like vulvar cancer, endometrium cancer, vaginal cancer, and fallopian tube cancer. Key drivers for market growth include investments from both the public sector and private sector, product approvals, and the success of notable treatments like Lynparza and Bevacizumab, particularly in the context of homologous recombination deficient (HRD)-positive advanced ovarian cancer.

Moreover, early screening initiatives and the adoption of targeted therapies, focusing on proteins and pathways associated with tumorigenesis, contribute to the market's expansion. The industry's focus on indications like vaginal and vulvar cancer, coupled with preventive measures such as the HPV vaccine, underscores a holistic approach to addressing gynecological cancers and driving the global market forward.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Type Outlook
  • Uterine cancer
  • Ovarian cancer
  • Cervical cancer
  • Others

• Modality Outlook
  • Chemotherapy
  • Targeted therapy
  • Hormonal therapy

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

Gynecological Cancers Therapeutics Market Scope
Report Coverage	Details
Page number	173
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 15.83%
Market Growth 2024-2028	USD 19.15 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	13.17
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 43%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., Apotex Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.
Market dynamics	Parent market growth analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Gynecological Cancers Therapeutics Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size and its contribution n of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch